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The recognition that different host  defense  mechanisms against injury  are  closely 
interrelated has permitted a  clearer understanding  of the processes of inflammation, 
blood coagulation, and activation of serum proteolytic enzyme systems. Human blood 
platelets are cells primarily specialized for hemostasis. However, they have also been 
found  to possess  inflammatory functions characteristic  of polymorphonuclear leuko- 
cytes and may therefore play a  broader role in host defenses (1). 
Leukocytes  promote  inflammatory  responses  by  releasing  mediators  of  vascular 
permeability and mast cell degranulation,  bactericidal proteins,  chemotactic factors, 
and lysosomal enzymes that cause tissue damage  (2). Platelets also release mediators 
of vascular permeability  (3)  and  bactericidal proteins  (4)  and  possess  enzymes that 
damage elastic tissue and collagen (5,  6). 
This study has examined the role of platelets in the production of chemotactic 
activity for leukocytes and presents evidence that activation of the complement 
system  by  platelets  is  a  physiologic  process  that  forms  a  link  between  the 
hemostatic process and inflammation. 
Materials and Methods 
Preparation of Platelets and Platelet Fractions.--Human platelet  concentrates  were  pre- 
pared from whole blood anticoagulated with acid citrate dextrose and kindly supplied by the 
New York Blood Center and the Memorial Hospital (New York)  donor room. Platelets were 
separated and extensively washed by methods previously described in detail (3).  Contamina- 
tion by leukocytes was less than  1 per  104 platelets. The isolated platelets were briefly soni- 
cared  using  a  Branson  Sonifier  (Branson  Instruments  Co.,  Stanford,  Conn.)  and  were ex- 
tracted once with ice-cold 0.2 N  H2SO4 for 1 h. Acid extracts were cleared by centrifugafion 
at  12,000 g and were dialyzed against buffered saline for 4  h  at  10°C  before experimental 
use.  Dialyzed material was filtered through 0.45-/zm  pore filters (Millipore Corp.,  Bedford, 
Mass.)  and used immediately or stored at  --20°C for up to 2 wk. 
Isolated  platelet  granules  were  obtained  by  sucrose  density  gradient  centrifugation  of 
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homogenized, washed platelets (7). Both saline lysates and acid extracts were prepared from 
the granules. Protein content of preparations was measured by a modified Folin method (8). 
Washed fresh platelets for aggregation studies were prepared by the method of Ardlie (9) 
omitting apyrase from the final  suspending fluid.  Blood  was used fresh from single donors 
who had not ingested aspirin during the week before bleeding.  Platelet counts were performed 
by the method of Brecher and Cronkite (10). 
Preparation of Serum Substrates.--Normal human donors were bled by clean venipuncture 
using plastic syringes. The blood  was placed into sterile plastic tubes on ice without anti- 
coagulant and immediately centrifuged at 4000 g at 4°C for 20 rain  to yield native platelet- 
poor plasma. This was transferred to a sterile glass  tube and permitted to clot at room tem- 
perature. Platelet counts were performed on the platelet-poor plasma. After sterile removal 
of the fibrin clot, the residual serum, designated "plasma serum" (11), was used for chemo- 
taxis studies. Whole blood, clotted directly in sterile glass tubes, was used to provide "blood 
serum." 
Chemotaxis Studies.--The same donor provided the polymorphonuclear leukoeytes (PMN) 1 
and serum for any single experiment. Blood for PMN leukocyte preparation was mixed with 
10 U of heparin and 0.075 ml of methyl cellulose per ml of whole blood and permitted to settle 
by gravity in sterile plastic tubes at room temperature. After 1 h  the leukocyte-rich super- 
natant plasma was removed and centrifuged in siliconized  tubes at 77 g for 10 rain to sedi- 
ment the PMN leukocytes.  Residual red cells were removed by hypotonic lysis.  The leuko- 
cytes were  twice washed with  Gey's buffered salt  solution containing 0.1%  bovine serum 
albumin, pH 7.0, and resuspended in this medium at a  concentration of 2 X  10 ~ PMN/ml. 
Generation  of Chemotactic  Activity.  Chambers modified from  the  original  Boyden  type 
were used, fitted with micropore filters of 3.0 #m pore size. Mixtures of 0.15 ml of serum, 0.1 
ml of platelet protein, and 0.05-0.1  ml of buffer were incubated in sterile plastic tubes with 
agitation at 37°C for a  desired period (usually 30  min)  and were diluted fivefold  with cold 
buffered Eagle's minimal  essential medium  (MEM)  (Grand  Island  Biological  Co.,  Grand 
Island, N.  Y.).  The Sower compartment of the chemotaxis chambers was filled with the di- 
luted  incubation  mixture and  the upper  compartment with  1 X  10 ~ PMN.  All  tests were 
performed in duplicate. After incubation of the chambers for 21/.~ h at 37°C in moist air,  the 
filters  were removed, fixed in methanol, stained with hematoxylin, dehydrated, and cleared. 
Cell counts were made of PMN that had migrated entirely through the filter to the lower or 
far side, and were expressed as the mean of counts of two duplicate filters,  with five random 
high-power fields counted per filter. 
Platdet Aggregali6n.  Samples of washed platelets were aggregated with recording by the 
turbidimetric method of Born, using a Chrono-Log aggregometer (Chrono-Log Corp., Broom- 
all, Pa.) and a Bausch and Lomb VOM-5 recorder (Bausch and Lomb, Inc., Rochester, N. Y.). 
lnhibitors and Special Reagents.  Collagen,  adenosine diphosphate (ADP), soybean tryp- 
sin inhibitor, ethylenediaminetetraacetic acid,  tosyl arginine methyl ester (TAMe), benzoyl 
arginine methyl ester (BAMe), glycyl glycine ethyl ester (GGEE), and epsilon aminocaproic 
acid (EACA) were purchased from Sigma Chemical Corp. (St.  Louis,  Mo.). Purified alpha-2- 
macroglobulin from  human  plasma  was  the  gift  of  Dr.  Peler  Harpel,  Cornell  University 
Medical College.  Purified human  C3 and (75  were kindly provided by Dr.  Margaret Polley 
of Cornel[ University Medical College. Antibodies to C3 and (?5 were purchased from Cordis 
Laboratories Inc. (Miami, Fla.). 
RESULTS 
The intrinsic chemotactic activity of serum  was evaluated to determine the 
possible contribution made by platelets during clotting. Serum prepared from 
1 Abbreviations used in  this paper: ADP, adenosine diphosphate; MEM, Eagle's minimal 
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clotted  whole  blood  (here  termed  blood  serum)  has  been  observed  by other 
investigators to possess chemotactic activity without the addition of any known 
chemotactic  agent  (12).  Blood  was therefore  drawn  into  chilled  plastic  tubes 
and  immediately  centrifuged  to  sediment  all  erythrocytes,  leukocytes,  and 
platelets  before  the  supernatant  plasma  was  removed  and  permitted  to  clot. 
Serum prepared in this manner  (here termed plasma serum)  had little,  if any, 
chemotactic activity  (Fig.  1). As the  platelet  count  in the  centrifuged  plasma 
was  increased  by slower  centrifugation,  the  chemotactic  activity  proportion- 
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FIG. 1. The chemotactic  activity of serum derived from plasmas containing  varying plate- 
let concentrations  compared  with the activity of whole blood serum.  Chemotactic activity 
denotes  the total number of polymorphonuclear  leukocytes  that have migrated completely 
through a 3 /~m pore filter after 21/6 h incubation  at 37°C, as counted  over five high-power 
microscope fields. Each bar represents  mean of two duplicate  assays using serum with desig- 
nated platelet count.  This figure depicts  results  of a  single typical experiment  using blood 
from a single normal subject.  PPP, platelet-poor  plasma; PRP, platelet-rich  plasma. 
ately increased in the resultant serum. In order to evaluate the contribution  of 
platelet  constituents  to  serum  chemotactic activity,  the  serum  used  for sub- 
sequent experiments was prepared from platelet-poor plasma {plasma serum). 
Suspensions  of  washed  platelets  and  platelet  fractions  alone  possessed  no 
chemotactic activity for polymorphonuclear leukocytes in the absence of serum. 
However,  upon  incubation  of  platelet  protein  fractions  with  plasma  serum, 
marked  chemotactic  activity  appeared  (Fig.  2).  Platelet  granule  lysates  were 
significantly more active than whole platelet extracts. 
Washed platelets, suspended in buffer solution, were aggregated to determine 
whether  the  factor  that  generates  chemotactic  activity  in  serum  is  released 
from  the  ceils  {Table  I).  The  aggregating  agents  collagen,  epinephrine,  and 
ADP  alone were inactive.  Supernatant  fluid  from suspensions  of platelets  ag- 400 
PLATELET-DEPENDENT  CHEMOTAXIS 
gregated  with  collagen  and  epinephrine,  after  sedimentation  of  the  platelet 
aggregates,  generated  chemotactic  activity  in  serum.  The  supernatant  fluid 
from nonaggregated platelets or from platelets reversibly aggregated with ADP 
did not generate chemotactic activity. 
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FIG.  2.  Chemotactic activity generated in  plasma serum  by  platelet protein fractions. 
Each bar denotes the chemotactic activity produced by the designated amount of platelet 
protein incubated with 0.15 ml of fresh plasma serum for 30 min at 37°C and diluted five- 
fold with buffered MEM for chemotactic assay. The bar marked buffer indicates activity of 
serum incubated only with phosphate-buffered saline. 
TABLE I 
Release of Chemotaxis-Generating Factor from  Washed Platelets by Aggregation 
Supernatant from platelets* treated with  Aggregation  Chemotactic  activity:~ 
Buffer  None  15 
ADP, collagen,  or epinephrine without plate-  None  30 
lets 
ADP 1 #M  Reversible  35 
Collagen 10 #1 (4 mg/ml)  Yes  278 
Epinephrine 10/~M  Yes  220 
* Platelets washed in Ardlie buffer system, suspended at 200,000/#1. 
:~ Generated by incubation of 0.1  ml of platelet supernatant or aggregating agent, 0.15 
ml of serum, and 0.05 ml of buffer for 30 min at 37°C. Activity represents mean number of 
PMN per five high-power fields that have migrated through a 3 #m pore filter.  Mean value 
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Factors Influencing  the Generation of Chemotactic Activity by Platelet Protein.- 
Temperature: The generation of chemotactic activity in fresh serum by plate- 
let protein  was dependent  on  the  temperature  of incubation  (Fig.  3).  Very 
little activity appeared after incubation  at 0°C, while activity increased with 
increased temperatures up to 37°C. 
Duration of incubation: During incubation at 37°C, the chemotactic activity 
generated  increased with incubation  time to a  maximum  at 30 rain  (Fig. 4). 
Longer incubation periods resulted in a diminution of activity. 
ptt of incubation: The generation of chemotactic activity in serum by platelet 
protein also was dependent upon pH, with maximal  activity generated in the 
neutral  range,  pH 7.2-7.4  (Fig. 5). No activity was generated  at pH 3.8-4.0, 
the optimum range for many lysosomal cathepsins (13). 
Stability  of platelet protein: The  chemotaxis-generating  capacity  of human 
platelet acid extract was stable for weeks when stored at acid pH and 4°C or at 
neutral pH at  -20°C,  but was lost at neutral  pH upon storage at room tem- 
perature. The activity was stable to heating to 100°C for 10 min. 
Role of inhibitors: Exposure of the platelet extract to the enzyme inhibitors 
alpha-2-macroglobulin,  soybean  trypsin  inhibitor,  and  epsilon  aminocaproic 
acid (EACA)  rapidly abolished the capacity to generate  chemotactic activity 
in serum (Table II). Once activity was generated in serum the addition of these 
substances had little or no effect. Treatment  of the platelet extract with tosyl 
argininine methyl ester (TAMe) or benzoyl arginine methyl ester (BAMe) par- 
tially inhibited  its subsequent chemotaxis-generating  activity, whereas glycyl 
glycine ethyl ester (GGEE) was without significant effect (Table II). 
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FIO.  3.  Effect of incubation temperature on generation of platelet-dependent chemotactic 
activity in serum. Each point represents cheraotactic activity produced after 30 rain incuba- 
tion of 40/~g of human platelet acid extract and 0.15 ral of plasma serum at pH 7.2. 1424  PLATELET-DEPENDENT  CHEMOTAXIS 
Optimum proportions  of platelet  protein  to serum substrate:  Maximal chemo- 
tactic activity was dependent upon the ratio of plateiet factor to serum (Table 
III). For a constant amount of serum, increasing chemotactic activity was gen- 
erated by incubation with increasing amounts of platelet protein up to 40-50 #g 
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FIG. 4. Effect of duration of incubation on generation of chemotactic activity. Each point 
represents mean chemotactie activity generated during incubation of 40 ~g of human platelet 
acid extract and 0.15 ml of plasma serum at pH 7.2.  Incubations were terminated by fivefold 
dilution with MEM and chilling in ice until chemotactie assay. 
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FIG.  5.  Effect on incubation pH on generation of chemotactic activity. Each point repre- 
sents the mean chemotactic activity generated during incubation of 40 #g of human platelet 
acid  extract and 0.15  ml of plasma serum at indicated pH for 30  min at 37°C.  Incubation 
was terminated by fivefold dilution with MEM and adjustment of pH to 7.2 for chemotactlc 
assay. BABETTE B.  WEKSLER AND  C.  ELAINE COIYPAL 
TABLE  II 
Effect  of  Inhibitors  on  Generation  of  Chemotactic  Actizity  by  Platelet  Protein 
1425 
Test substances*  Chemotactic activity  generated;  Inhibition 
Buffer (no inhibitor) 
Soybean trypsin inhibitor (0.15 mg/ml) 
Alpha-2-macroglobulin (0.12 mg/ml) 
Epsilon amino caproic acid (0.03 M) 
Tosyl arginine methyl ester (0.03 M) 
Benzoyl arginine methyl ester (0.03 M) 
Glycyl glycine ethyl ester (0.03 M) 
% 
363 
71  81 
24  93 
104  71 
43  89 
302  16 
330  9 
* Final concentration in incubation mixture. 
:~ 0.15 ml of plasma serum incubated with mixture of test substances and 35/zg of platelet 
acid extract for 30 min at 37°C. 
TABLE  III 
Protein Content of Platelet Extract in Relation to Generation of Chemotactic ActiTity 
Platelet protein*  Relative chemotactic activity:~ 
ug/assay  % 
10  70 
20  84 
30  87 
40  98 
50  93 
70  83 
100  57 
* Micrograms of platelet acid extract  incubated with 0.15 ml of fresh plasma serum for 
30 min at 37°C and diluted fivefold for chemotactic assay. 
:~ Chemotactic activity at each level tested  in a  single experiment was expressed as a 
percent of peak value. The results given above are the average of normalized values from 10 
experiments with eight different preparations of platelet protein. 
of whole platelet protein per 0.15 ml of serum. Larger amounts of platelet pro- 
tein tended to yield decreased activity. 
Serum requirements: Fresh serum supported generation of chemotactic activity 
by platelet protein extracts. Plasma anticoagulated with heparin or with sodium 
citrate did not generate activity. If serum was heated to 56°C for 30 min before 
incubation with platelet extract, no chemotactic activity was produced (Table 
IV). Treatment of serum with 0.001  M  hydrazine, with heparin, or with  1 M 
KSCN all prevented the generation of chemotactic activity by platelet protein. 
Aged serum, kept at room temperature overnight or at  10°C for several days, 
was  also  inactive. The  addition  of  0.001-0.01  M  disodium EDTA  to  fresh 
plasma serum, however, did not interfere with subsequent generation of chemo- 
tactic activity but rather enhanced its production. 1426  PLATELET-DEPENDENT  CHEMOTAXIS 
From the above studies it appeared likely that serum complement activity 
was related to the platelet-dependent generation of chemotactic activity in the 
serum. The following studies were carried out to determine the contribution of 
specific complement components. 
Preincubation of serum substrate  with  specific antibody to  C3  and  C5  did 
not generate chemotactic activity (Fig. 6). When antibody-treated serum was 
incubated with platelet protein, chemotactic activity was readily generated in 
serum  exposed to  anti-C3  antibody,  but  activity was  markedly inhibited  in 
serum exposed to anti-C5 antibody. The addition of either anti-C3 or anti-C5 
antibody to the serum-platelet protein mixture at  the  end of the incubation 
period did not inhibit the newly generated chemotactic property. 
To test the requirement for complement directly, purified human C3 and C5 
were substituted as the substrate for the platelet protein (Fig. 7) and serum was 
TABLE  IV 
Effect of Serum  Treatment  of Chemotactic Activity Generated by Platelet Protein 
Substrate*  Chemotactic activity~t  Inhibition 
Fresh plasma serum 
Heated serum (30 min at 56°C) 
Hydrazine-treated serum (0.015  M) 
Serum  +  EDTA 0.01  M 
% 
363  0 
7  99 
8  98 
403  Enhanced 
* 0.15 ml of substrate incubated with 35/~g of platelet extract for 30 min at 37°C, pH 7.2. 
:~ Mean cell count per five high-power fields in duplicate filters. 
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Fin. 6. Effect of anticomplement antisera on generation of platelet-dependent chemotactic 
factor in plasma serum. Stippled bars represent chemotactic activity generated by treatment 
of plasma  serum  with  buffer,  anti-C3,  or  anti-C5  in  the  absence of platelet protein.  Solid 
bars represent chemotactic activity generated in plasma serum by platelet protein after pre- 
incubation  of serum  with  buffer,  anti-C3,  or  anti-C5  (bars  marked  "start").  Anti-C3,  and 
anti-C5 were also added  to incubation mixture of plasma serum and platelet protein at  end 
of the 30 rain incubation at 37°C  (bars marked  "end"). BABETTE  B.  WEKSLER  AND  C.  ELAINE  COUPAL  1427 
omitted. Incubation with the individual complement components resulted in 
the generation of chemotactic activity only from C5. 
DISCUSSION 
The mechanisms governing leukocyte chemotaxis, an important early step in 
the development of inflammatory reactions, have been extensively studied in 
the past decade. The central role of complement-derived chemotactic factors in 
inflammation has been clearly defined (14, 15), and the reinforcement of chemo- 
taxis by the inflammatory exudate cells themselves interacting with serum com- 
plement has been shown to be a means for amplifying or propagating the inflam- 
matory response. Ward and Hill (16) have demonstrated that an enzyme in the 
lysosomal granules of PMN  leukocytes from rabbits  produces  a  CS-derived 
chemotactic peptide, while Snyderman, Shin, and Dannenberg (17) have shown 
that monocytes can generate a similar, perhaps not identical, chemotactic factor 
from C5. A variety of injured or infected tissues has been shown to liberate a 
chemotactic fragment from C3 or C5 (18-20). 
In previous studies on inflammatory properties of platelets (3,  21,  22)  we 
showed that an acid extract of human platelet granules both induced an increase 
in vascular permeability in rabbit skin and produced an intense exudation of 
PMN leukocytes at the injection site. The first, but not the second, phenomenon 
was related to histamine release. The present investigation was aimed at defin- 
ing the mechanism of this leukocyte response. 
The data presented here indicate that a protein fraction present in human 
platelets,  itself lacking any chemotactic property,  can  generate  chemotactic 
activity in fresh  serum. Much of the  "background" or intrinsic chemotactic 
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Fro.  7.  Generation of  cheinotactic activity  from  purified  complement components by 
human platelet acid extract. Circles  (O)  indicate cheinotactic activity generated from puri- 
fied human C5 by incubation with 50/~g of human platelet acid extract for 30 Inin at 37°C 
at pH 7.2. Triangles (A) indicate results when human C3 was used as substrate. 1428  PLATELET-DEPENDENT CttE?cIOTAXIS 
activity of serum detected by other investigators appears to be related to the 
presence of platelets during clotting. If cell-free  plasma is clotted the chemo- 
tactic property of the serum virtually disappears, whereas platelet-rich plasma 
when clotted yields serum of high chemotactic activity. The factor responsible 
for production of chemotactic activity in plasma serum is released from washed 
platelets during aggregation by agents such as collagen and epinephrine, sug- 
gesting that it is a normal platelet constituent released under physiologic con- 
ditions as part of the platelet release reaction. 
The platelet factor that generates chemotactic activity in serum resides in 
the same acid-extractable protein fraction as the vascular permeability factor 
previously described.  The  activity can,  similarly, be further localized to  the 
lysosomal granules of platelets. This platelet protein fraction acts upon the fifth 
component of complement to liberate chemotactic activity for PMN leukocytes 
in a manner very similar to the C5-cleaving factor from rabbit PMN leukocyte 
granules described by Ward and Hill  (16).  Both  the platelet factor and  the 
leukocyte C5-cleaving factor have maximum activity at neutral pH and at body 
temperature  and  demonstrate  similar  optima  for  incubation  time  and  sub- 
strate:factor ratios. Inhibitor patterns are also generally parallel. 
Studies employing inhibitors of complement,  specific  anticomplement anti- 
sera, and purified complement components indicate that the platelet factor acts 
directly upon C5 to liberate a chemotactic principle. The generation of chemo- 
tactic activity in plasma serum is inhibited by pretreatment with anti-C5 anti- 
serum  but  not  by antibody against  C3.  EDTA,  which inhibits  the  classical 
pathway of complement activation (23) and in higher concentration (0.01 M) 
the alternate mechanism as well (24), does not inhibit the generation of chemo- 
tactic activity in serum by the platelet factor. That EDTA actually enhances 
the  expression  of  chemotactic  activity  by  the  platelet-dependent  pathway 
(Table IV) may reflect an EDTA-mediated protection of the chemotactic frag- 
ment  from  complement-inactivating  substances  present  in  serum.  This  en- 
hancing effect of EDTA upon platelet-dependent chemotactic activity contrasts 
with the inhibition by EDTA of PMN leukocyte granule-dependent generation 
of chemotactic activity from C5 (16). 
The demonstration that human platelets contain and during aggregation re- 
lease an activity that generates chemotactic fragments from C5 provides another 
clear  parallel  between  the  inflammatory activities of platelets  and  of PMN 
leukocytes. This physiologic resemblance reflects the evolutionary heritage of 
the hemocyte; moreover, it shows that the specialized  hemostatic cell and the 
specialized inflammatory cell share common functional capabilities. Since plate- 
lets remain essentially intravascular, their possession of a chemotaxis-generating 
system offers a platelet-dependent mechanism for the initiation of PMN leuko- 
cyte responses to vascular injury. It also provides for generation of chemotactic 
activity during the process of blood coagulation. This may promote the invasion 
of clots by leukocytes for clot resolution and lysis. BABETTE  B.  WEKSLER  AND  C.  ELAINE  COUPAL  1429 
The existence of this platelet-dependent chemotactic pathway stresses the 
close relationship between the processes of hemostasis and of inflammation, in 
both of which complement activation plays a pivotal role. Several recent studies 
have indicated that complement activation mediates platelet damage and hy- 
percoagulability. Normal blood clotting in the rabbit depends on the presence 
of the sixth component of complement (25), and the platelet release reaction in 
response to endotoxin or antigen-antibody complexes is defective in C6-deficient 
animals (26).  In guinea pigs,  endotoxin produces platelet damage, thrombo- 
cytopenia, and a shortened clotting time if the complement sequence is intact 
(27). In C4-deficient animals thrombocytopenia or shortened clotting time do 
not follow after endotoxin injection. Thus, in these  two species  complement 
activation is important in the development of inflammatory responses to intra- 
vascular stimuli mediated by platelets.  The present study suggests that the 
relationship between platelets and complement in inflammation also proceeds 
in the opposite direction, so that platelet factors may directly activate comple- 
ment components. 
SUMMARY 
A protein fraction extracted from the lysosomal granules of human platelets 
generated chemotactic activity for polymorphonuclear leukocytes when incu- 
bated with fresh serum. The platelet factor was also released during platelet 
aggregation with collagen or epinephrine and appeared to be released during 
blood clotting. Heated serum did not support the platelet-dependent generation 
of chemotactic activity. Treatment of fresh serum with antibody to the fifth 
component of  complement also prevented  development of  activity. Purified 
human C5 but not C3 yielded chemotactic activity upon incubation with the 
platelet factor. Thus, human platelets are capable of stimulating chemotaxis via 
complement activation in a  manner similar to leukocytes, and may therefore 
participate in the early stages of inflammation. 
The authors gratefully express their appreciation  to  Dr.  Ralph  Naehman for his advice 
and encouragement. 
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